Anumana’s Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag
Related Articles
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)November 07, 2022
Anumana and AliveCor Collaborate to Advance ECG-AI Algorithms for Early Detection of Cardiac Diseases on Kardia Devices
Anumana announces collaboration with AliveCorJanuary 07, 2025
Mayo Clinic launches two joint ventures to build, commercialize diagnostic AI tools
Med City News: Mayo Clinic struck two joint ventures to develop and commercialize AI diagnostic tools. The idea was to develop algorithms to support clinicians’ decisions, starting with a suite…April 13, 2021
Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)
Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by…February 14, 2023